AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01903954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly
Study NCT01903954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Orally b.i.d.
Study NCT01903954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg orally daily
Study NCT01903954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg orally daily
Study NCT01903954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
Study NCT04191863 — intervention group
Intervention type: OTHER
Intervention: Clinical, EEG and laboratory assessment at presentation
Description: * The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG.
Study NCT04191863 — intervention group
Intervention type: DRUG
Intervention: Valproate
Description: valproate monotherapy
Study NCT03757702 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
Study NCT02731612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study NCT01918566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tap water
Study NCT02645630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right Cervical Manipulation
Description: We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
Study NCT02645630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Cervical Manipulation
Description: We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
Study NCT02645630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Cervical Manipulation
Description: The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
Study NCT01517386 — intervention group
Intervention type: PROCEDURE
Intervention: thoracic surgery
Description: unilateral thoracic surgery under paravertebral block and general anesthesia
Study NCT01983774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Study NCT01983774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study NCT03809819 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic Vecchietti vaginoplasty
Description: Patients who underwent laparoscopic Vecchietti vaginoplasty
Study NCT03809819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FSFI questionnaire
Description: Completion of FSFI questionnaire
Study NCT03809819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6 questionnaire
Description: Completion of UDI-6 questionnaire
Study NCT03809819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7 questionnaire
Description: Completion of IIQ-7 questionnaire
Study NCT02467842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria
Study NCT02467842 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NBP607-Y
Description: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata
Study NCT02467842 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NBP607-V
Description: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
Study NCT02820506 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLN mapping and removal of PET-positive lymph nodes
Description: Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
Study NCT06136130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tortoise Positioning Material Group
Description: Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
Study NCT02423980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Study NCT01791101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study NCT03526510 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventionally Fractionated versus Hypofractionated Boost
Study NCT03526510 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated versus Hypofractionated Boost
Study NCT02551029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin
Study NCT02551029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00875290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time glucose sensor
Description: Children assigned to this intervention will use a real-time sensor continuously
Study NCT04617015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide
Description: All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
Study NCT04306653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: patients with acute gout will receive 100 IU ACTH IM
Study NCT04306653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: patients with acute gout will receive 6 mg of betamethasone
Study NCT05606055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
Description: This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
Study NCT01918566 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
Study NCT03611179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)
Study NCT03531099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment with focal HIFU
Description: HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
Study NCT03531099 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PSA dosage
Description: PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
Study NCT03531099 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA dosage
Description: PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
Study NCT03531099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI exam will be regularly performed during patient follow up.
Study NCT03531099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam will be regularly performed during patient follow up.
Study NCT05606055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
Description: This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
Study NCT04228432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dedicated and coordinated monitoring
Description: * Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6.
Study NCT04067661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIP
Description: The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
Study NCT04067661 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
Study NCT01306383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SODIS Bottle
Description: SODIS Bottles used by SODIS group to treat their drinking water
Study NCT03610373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modular Approach to Therapy for Children (MATCH)
Description: MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
Study NCT03610373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children (MATCH)
Description: MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
Study NCT04088110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
Study NCT04088110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
Study NCT04088110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study NCT03582995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap Surgery for root coverage with Alloderm and xenograft
Description: A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
Study NCT03582995 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel Surgery for root coverage with Alloderm and xenograft
Description: A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
Study NCT00002921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Study NCT03531099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
Study NCT03531099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
Study NCT00002921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study NCT03757377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BackBeat Moderato System
Description: Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
Study NCT03531099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatic biopsies
Description: Prostatic biopsies will be regularly performed during patient follow up.
Study NCT03531099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic biopsies
Description: Prostatic biopsies will be regularly performed during patient follow up.
Study NCT03906006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: Drug: ABP-671, single oral dose
Study NCT03757377 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BackBeat Moderato Sytsem
Description: Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
Study NCT06525233 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy and rehabilitation
Description: The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
Study NCT02410382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral dexamethasone 4 mg bid for 14 days
Study NCT02410382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo
Study NCT01959243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Ophthalmic solution to be applied as directed.
Study NCT01959243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Ophthalmic solution to be applied as directed.
Study NCT01959243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.
Study NCT01959243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.
Study NCT01959243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Study NCT01959243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Study NCT01158391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTrainer® Intervention
Study NCT01158391 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Study NCT04514211 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: General anesthesia using propofol infusion
Study NCT04514211 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: General anesthesia using sevoflurane
Study NCT03196531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
Study NCT03196531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
Study NCT03080363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10 ml %0.5 bupivacaine
Study NCT03080363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10 ml %2 lidocaine
Study NCT03906006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Other: Placebo, single oral dose
Study NCT02166827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroAD
Description: Synchronized TMS and cognitive stimulation to 6 brain areas.
Study NCT02166827 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS+Cog
Description: Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
Study NCT03204981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramural Needle Ablation
Description: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
Study NCT03204981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: standard ablation
Study NCT02659527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga- PSMA-HBED-CC
Description: Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
Study NCT02659527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga- PSMA-HBED-CC
Description: Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
Study NCT02659527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biograph mMR, Siemens
Description: All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
Study NCT02659527 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biograph mMR, Siemens
Description: All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
Study NCT00939809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urokinase-Derived Peptide A6
Description: Given SC
Study NCT00939809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01357265 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Influenza Vaccine
Description: This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Study NCT01799499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 hydrogel
Study NCT00854594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)
Description: The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
Study NCT01163214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve Block
Description: Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
Study NCT00922714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
Study NCT00922714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline (placebo)
Description: NaCl 0.9 g/L